Therapeutic Workshop
Drug-Device Convergence: "Beyond Drug-Eluting Stents"
Wednesday, February 13, 2008
9:30 AM
Louis XVI Suite Center/West
While not a new concept to marry drugs and devices, the union is, in many ways, still in the honeymoon phase. New ideas continue to be tested, multi-year deals are signed, and the resulting combinations are proving to be worthwhile investments for many biotech, pharmaceutical, device and diagnostic companies, as well as for investors. These blended products? values in the worldwide marketplace are anticipated to grow at an average of 14% annually to more than $11 billion in 2010. A major catalyst for this growth is drug-eluting stents but there are many other dual products in discovery and development that seek to improve the efficacy, safety and delivery of new medicines. This panel will focus on emerging drug and device combinations.
Moderators
- Caroline V. Corner, Ph.D.; Senior Research Analyst, Pacific Growth Equities, LLC
Panelists
- David Cassak; Managing Partner, Windhover Information Inc.
- Lothar Krinke, Ph.D.; Vice President Business Development, Medtronic, Inc.
- Charles E. Hart, Ph.D.; Chief Scientific Officer and Vice President, BioMimetic Therapeutics, Inc.
- Llew Keltner, M.D., Ph.D.; President, CEO and Director, Light Sciences Oncology, Inc.
- Shawn P. Cain; President and Chief Executive Officer, Arbios Systems, Inc.
Who's Who
Expert: David Cassak is a Managing Partner of Windhover Information and has been involved with the health care industry for more than 20 years. Mr. Cassak earned a BA from Drew University and did graduate work at Columbia and Princeton, earning an MA, with honors from the former, before joining, Cassak Publications Inc., a family-run business that published trade journals for the hospital and alternate site distribution industries. For much of the 1980s, he wrote and spoke frequently about the medical/surgical and hospital supply industries, before joining The Wilkerson Group, a health care consulting company, in 1988, as an editor of IN VIVO: The Business & Medicine Report. In 1989, Mr. Cassak, along with his partner Roger Longman, led a buyout of the publications business of TheWilkerson Group, forming Windhover Information Inc. In addition to IN VIVO, Windhover publishes other monthly reports, including START-UP: Windhover's Review of Emerging Medical Ventures and IN VIVO Europe Rx: Inside Europe's Biopharma Companies. Windhover also has an extensive database of health care transactions which has been turned into a Web-based electronic system, Strategic Intelligence Systems (SIS). SIS allows users to search for transactions by a variety of criteria, including deal structure, value, and therapeutic and scientific categories. Windhover also has a conference business and is well-known for, among others, its Pharmaceutical Strategic Alliances (New York), Euro-Biotech (Paris), Marketing Pharmaceutical Alliances (Philadelphia), and Bio-Windhover (Washington) meetings. Mr. Cassak writes extensively about the medical device and hospital supply industries for IN VIVO and START-UP and is a frequent speaker before various companies and industry trade groups.